Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

Table 4 Rates of adverse events

	CDDP group (n = 362)			Placebo group (n = 121)			P value
	Number of times	Number of cases	Percentage (%)	Number of times	Number of cases	Percentage (%)
Adverse events	143	92	25.41	65	36	29.75	0.344
Mild	108	73	20.17	50	32	26.45	0.162
Moderate	32	26	7.18	14	11	9.09	0.554
Severe	3	3	0.83	1	1	0.83	> 0.999
Serious adverse events	6	6	1.66	1	1	0.83	0.686
Adverse events occurring in at least 1% of participants in one or more groups
Infections	21	18	4.97	7	6	4.96	1.000
Urinary tract infection	6	6	1.66	4	4	3.31	0.278
Upper respiratory tract infection	8	7	1.93	1	1	0.83	0.686
Nervous system disorders	2	2	0.55	8	8	6.61	0.000
Dizziness	2	2	0.55	4	4	3.31	0.037
Blood and lymphatic system disorders	3	3	0.83	2	2	1.65	0.603
Coagulation disorder	3	3	0.83	2	2	1.65	0.603
Investigations	52	39	10.77	26	16	13.22	0.509
Increased gamma-glutamyl transferase	2	2	0.55	2	2	1.65	0.262
Positive urine leukocytes	5	5	1.38	8	6	4.96	0.033
Increased blood creatine phosphokinase	5	5	1.38	3	3	2.48	0.420
Increased blood creatinine	5	4	1.10	1	1	0.83	1.000
Decreased blood glucose	5	5	1.38	1	1	0.83	1.000
Increased blood glucose	9	8	2.21	1	1	0.83	0.461
Decreased platelet count	0	0	0.00	2	2	1.65	0.062

CDDP: Compound danshen dripping pill.